Delivering therapies to the brain remains a major challenge due to the limited permeability of the blood-brain barrier. In a ...

The global Central Nervous System (CNS) therapeutic market is projected to reach US$ 235.87 billion by 2033. This growth is ...

Iopofosine I 131 Active in Treating Malignancies in the Brain; Confirmed Response in CNS Lymphoma Provides Additional Validation for Continued Development of Iopofosine in Multiple CNS Malignancies ...

CNS-directed AAV gene therapy shows milder immune responses compared to systemic administration, reducing peripheral immune activation and systemic toxicities. Direct CNS delivery can bypass ...

In a recent study published in Nature, researchers developed Sturgeon, a patient-agnostic transfer-learned neural network, to enable molecular subclassification of central nervous system (CNS) ...

The "Central Nervous System Therapeutics Market - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global market for Central Nervous System Therapeutics was ...

- Portfolio available in 60+ markets and deepens our CNS footprint in Brazil, South Africa, France and Italy BASILDON, England--(BUSINESS WIRE)--PRESS RELEASE – FOR TRADE, BUSINESS AND MEDICAL MEDIA ...

DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR ® artificial intelligence (AI) and machine learning (ML) platform to ...

DUBLIN--(BUSINESS WIRE)--The "Central Nervous System Therapeutics Market - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global market for Central Nervous ...